Abu Dhabi's G42 forms big data JV with Israeli defence company Rafael

The joint venture, called Presight.AI, will have a research and development site in Israel and will develop products for sectors including banking, healthcare and public safety, to be sold in Israel, UAE and internationally

  
Workers install Rafael Advanced Defense Systems fighter jet weapons, before the opening of the 52nd Paris Air Show at Le Bourget Airport near Paris, France June 17, 2017.

Workers install Rafael Advanced Defense Systems fighter jet weapons, before the opening of the 52nd Paris Air Show at Le Bourget Airport near Paris, France June 17, 2017.

Reuters/Pascal Rossignol

DUBAI - Abu Dhabi-based technology company Group 42 (G42) has formed a joint venture with Israel's state-owned Rafael Advanced Defense Systems to commercialise artificial intelligence and big data technologies, the companies said on Monday.

The joint venture, called Presight.AI, will have a research and development site in Israel and will develop products for sectors including banking, healthcare and public safety, to be sold in Israel, the United Arab Emirates and internationally.

Israel and the UAE agreed to normalise relations in August, triggering a number of announcements from businesses stating their intention to cooperate across the two countries.

UAE Ambassador to Israel Mohamad al-Khaja said the joint venture strengthened the relationship between Israel and the UAE and opportunities for bilateral economic growth.

G42 is an Abu Dhabi-based artificial intelligence and cloud computing company set up in 2018 which works with government and private clients. In September it became the first UAE company to open an international office in Israel.

UAE national security advisor Sheikh Tahnoon bin Zayed Al Nahyan is its chairman and a shareholder. Abu Dhabi's sovereign fund Mubadala in November invested in G42 and last week U.S. private-equity firm Silver Lake invested to help the company expand.

G42 rose to prominence last year as it led Phase III clinical trials of a vaccine developed by Sinopharm's China National Biotec Group (CNBG) in the UAE and regional countries, as well as offering medical diagnostic services.

The joint venture agreement is subject to regulatory approvals by Israeli and UAE authorities.

(Reporting by Lisa Barrington; Editing by Edmund Blair, William Maclean) ((lisa.barrington@thomsonreuters.com;))

More From Technology